Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality.

@article{Sellar2017TargetingAS,
  title={Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality.},
  author={Rob S Sellar and Julie-Aurore Losman},
  journal={Hematology/oncology clinics of North America},
  year={2017},
  volume={31 4},
  pages={565-576}
}
Clonal myeloid disorders are characterized by genetic alterations that activate cytokine signaling pathways and stimulate cell proliferation. These activated signaling pathways have been extensively studied as potential therapeutic targets, and tyrosine kinase inhibitors have indeed had extraordinary success in treating BCR/ABL-positive chronic myeloiud… CONTINUE READING